<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: <z:mp ids='MP_0003674'>Oxidative stress</z:mp>-induced cell damage is reported to contribute to the pathogenesis of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>/reperfusion injury </plain></SENT>
<SENT sid="1" pm="."><plain>This study investigated the neuroprotective effect of nebivolol against <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>/reperfusion insult in rats </plain></SENT>
<SENT sid="2" pm="."><plain>MAIN METHODS: The model adopted was that of surgically-induced forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, performed by means of bilateral common carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 1h, followed by reperfusion for 24 h </plain></SENT>
<SENT sid="3" pm="."><plain>The effects of 5 and 10 mg/kg nebivolol, treated for 7 days prior to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion insult, were investigated by estimating endothelial and inducible nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthases (eNOS and iNOS) protein expressions and assessing <z:mp ids='MP_0003674'>oxidative stress</z:mp>-related biochemical parameters in the rat forebrain </plain></SENT>
<SENT sid="4" pm="."><plain>Also, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume measurement and histopathological study of the forebrain were examined </plain></SENT>
<SENT sid="5" pm="."><plain>KEY FINDINGS: Administration of nebivolol increased eNOS expression with simultaneous decrease in iNOS expression in a dose dependent manner </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, nebivolol inhibited <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion-induced <z:mpath ids='MPATH_63'>depletion</z:mpath> of reduced <z:chebi fb="0" ids="16856">glutathione</z:chebi> level and decreased the elevated total nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> end production and malondialdehyde levels, <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase and <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase activities </plain></SENT>
<SENT sid="7" pm="."><plain>A notable finding is that catalase activity was not changed in response to either <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion insult or nebivolol treatment </plain></SENT>
<SENT sid="8" pm="."><plain>However, the results confirmed that nebivolol significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and alleviated <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion-induced histopathological changes </plain></SENT>
<SENT sid="9" pm="."><plain>SIGNIFICANCE: The present study demonstrates the neuroprotective effect of nebivolol against <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>/reperfusion insult </plain></SENT>
<SENT sid="10" pm="."><plain>Neuroprotection observed with nebivolol may possibly be explained by regulating eNOS and iNOS expressions and by inhibition of <z:mp ids='MP_0003674'>oxidative stress</z:mp>-induced injury </plain></SENT>
<SENT sid="11" pm="."><plain>Thus, nebivolol may be considered as a potential candidate for treatment in patients who are prone to <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>